Biora Therapeutics, Inc.

Progenity, Inc.

Canary Medical Switzerland Ag

Tuyen Nguyen

Mitchell Lawrence Jones

Christopher Loren Wahl

Mark Sasha Drlik

Nathan John Muller

Jeffrey A Shimizu

Nelson Quintana

Iman Niknia

Nicholas Mark Salt

Edward Mudge

Nia Eleri Stevens

Stuart Robert Abercrombie

Christopher Ian Bunce

Kevin Howe

Pejman Rahimian

Jeffrey Mendel Gross

Peter J Schiller

Aaron Olafur Laurence Philippsen

Ryan Elliott Jones

Mark A Adler

Paul Charlesbois

Joshua Ben Hayes

Luke Aaron Mills

Paul Alexander Hulme

Timothy Park

Diego Ariel Sorrentino

Steven Cazarez

A smart medical device includes a structure configured to be at least partially implanted in a body, and an electronics cartridge that is configured to be inserted into the structure after the structure is implanted in the body. The structure may be a cannulated screw for use in treating bone fractures. The medical device includes an impedance sensor for monitoring and reporting on the healing state of bone fractures. The sensor includes components of the electronics cartridge and electrodes that are either associated with the cannulated screw or with the insertable electronics cartridge.

Medical device for implanting in boney tissue and characterization of bone fractures

Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

A method of treating a disease or condition in a subject in need thereof is disclosed. The method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject by orally administering an ingestible device comprising the dispensable substance to the subject. The ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist. The ingestible device releases the dispensable substance as at least one jet to a desired location of the GI tract of the subject.

An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized chamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Growing community of inventors

Victoria, Canada

Tuyen Nguyen